IMA
Price:
$6.78
Market Cap:
$75.81M
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Industry
Biotechnology
IPO Date
1998-02-27
Stock Exchange
NASDAQ
Ticker
IMA
According to ImageneBio Inc’s latest financial reports and current stock price. The company's current PE Ratio is -1.42. This represents a change of -96.00% compared to the average of -35.53 of the last 4 quarters.
The mean historical PE Ratio of ImageneBio Inc over the last ten years is -239.41. The current -1.42 PE Ratio has changed -40.69% with respect to the historical average. Over the past ten years (40 quarters), IMA's PE Ratio was at its highest in in the December 2021 quarter at 482.33. The PE Ratio was at its lowest in in the June 2020 quarter at -266.54.
Average
-239.41
Median
-158.68
Minimum
-818.63
Maximum
-14.47
Discovering the peaks and valleys of ImageneBio Inc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 143.00%
Maximum Annual PE Ratio = -14.47
Minimum Annual Increase = -89.41%
Minimum Annual PE Ratio = -818.63
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -19.29 | 33.27% |
| 2023 | -14.47 | -13.84% |
| 2022 | -16.80 | -89.41% |
| 2021 | -158.68 | -48.99% |
| 2020 | -311.07 | -62.00% |
| 2019 | -818.63 | 143.00% |
The current PE Ratio of ImageneBio Inc (IMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-16.85
5-year avg
-104.06
10-year avg
-239.41
ImageneBio Inc’s PE Ratio is greater than Connect Biopharma Holdings Limited (-3.90), less than InflaRx N.V. (-1.41), greater than Kalaris Therapeutics Inc (-2.14), greater than Shattuck Labs, Inc. (-3.91), greater than Context Therapeutics Inc. (-2.87), less than Sutro Biopharma, Inc. (-0.37), less than Artiva Biotherapeutics, Inc. (-1.28), less than Ovid Therapeutics Inc. (-0.06), less than Metagenomi, Inc. Common Stock (-0.76), greater than Quince Therapeutics, Inc. (-3.43),
| Company | PE Ratio | Market cap |
|---|---|---|
| -3.90 | $141.98M | |
| -1.41 | $74.52M | |
| -2.14 | $110.72M | |
| -3.91 | $142.27M | |
| -2.87 | $94.64M | |
| -0.37 | $79.86M | |
| -1.28 | $92.66M | |
| -0.06 | $115.21M | |
| -0.76 | $67.21M | |
| -3.43 | $200.45M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImageneBio Inc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ImageneBio Inc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ImageneBio Inc's PE Ratio?
How is the PE Ratio calculated for ImageneBio Inc (IMA)?
What is the highest PE Ratio for ImageneBio Inc (IMA)?
What is the 3-year average PE Ratio for ImageneBio Inc (IMA)?
What is the 5-year average PE Ratio for ImageneBio Inc (IMA)?
How does the current PE Ratio for ImageneBio Inc (IMA) compare to its historical average?